NCT06090110

Vagal Nerve Stimulation in Irritable Bowel Syndrome

Clinical Efficacy of Transcutaneous Auricular Vagal Nerve Stimulation in Irritable Bowel Syndrome and the Potential Predictive Role for the Vagal-Autonomic Neurosignature
Maastricht University·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Irritable Bowel Syndrome
Drug/Device/Intervention
Vagal Nerve Stimulation
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Maastricht University
Location
Maastricht, Netherlands
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Nov 01, 2026
Enrollment
166 participants
Primary outcome

Clinical meaningful decrease in severity of GI-symptoms

Summary

This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal
 nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks
 of treatment with a vagal nerve stimulator. The main objectives are:
 
 - To evaluate the clinical response, defined as a decrease of at least 50 points on the
 IBS-SSS questionnaire, of the treatment.
 
 - To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment
 registration of symptom profiles, autonomic responses and imaging of neuronal activity
 as a reaction to stress is able to predict therapeutic response to tVNS accurately.
 
 - To evaluate the effect of treatment on quality of life
 
 - To evaluate the effect of treatment on depression
 
 - To evaluate the effect of treatment on anxiety Participants will be asked to wear a
 wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a
 functional brain MRI will be performed.
 
 In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks
 at home. The comparison group will receive the same device but with a non-conducting
 electrode.
 
 Patients fill out weekly questionnaires during the treatment period and at follow-up moments
 3 and 6 months after finishing the treatment period.

ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06090110
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06090110 through Pure Global AI's free database. This phase not specified trial is sponsored by Maastricht University and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 166 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.